Skip to main content
PMC home page
Canadian Medical Association Journal logoLink to Canadian Medical Association Journal
. 1983 Oct 15;129(8):842–844.

Efficacy of ketoprofen in treating primary dysmenorrhea.

S Gleeson, J Sorbie
PMCID: PMC1875644  PMID: 6351994

Abstract

A 6-month double-blind crossover trial compared ketoprofen with placebo in the treatment of primary dysmenorrhea in 27 women who satisfied explicit inclusion and exclusion criteria. The response to treatment was assessed with a pain scale and a disability scale and by noting amelioration of associated symptoms, such as nausea, vomiting, diarrhea, fatigue, dizziness and headache. Ketoprofen was significantly superior to placebo in relieving the pain (p less than 0.001), disability (p less than 0.001) and headache (p less than 0.01) associated with menstruation. No order effect of treatment was observed. Adverse effects were few and minimal.

Full text

PDF
842

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersson K. E. Side-effects of prostaglandin synthetase inhibitors. Acta Obstet Gynecol Scand Suppl. 1979;87:101–104. doi: 10.3109/00016347909157801. [DOI] [PubMed] [Google Scholar]
  2. Bray M. A., Gordon D. Prostaglandin production by macrophages and the effect of anti-inflammatory drugs. Br J Pharmacol. 1978 Aug;63(4):635–642. doi: 10.1111/j.1476-5381.1978.tb17276.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Budoff P. W. Use of mefenamic acid in the treatment of primary dysmenorrhea. JAMA. 1979 Jun 22;241(25):2713–2716. [PubMed] [Google Scholar]
  4. Bygdeman M., Bremme K., Gillespie A., Lundström V. Effects of the prostaglandins on the uterus. Prostaglandins and uterine contractility. Acta Obstet Gynecol Scand Suppl. 1979;87:33–38. doi: 10.3109/00016347909157787. [DOI] [PubMed] [Google Scholar]
  5. Chan W. Y., Dawood M. Y., Fuchs F. Relief of dysmenorrhea with the prostaglandin synthetase inhibitor ibuprofen: effect on prostaglandin levels in menstrual fluid. Am J Obstet Gynecol. 1979 Sep 1;135(1):102–108. [PubMed] [Google Scholar]
  6. Dawood M. Y. Dysmenorrhoea and prostaglandins: pharmacological and therapeutic considerations. Drugs. 1981 Jul;22(1):42–56. doi: 10.2165/00003495-198122010-00003. [DOI] [PubMed] [Google Scholar]
  7. Diamond S., Medina J. L. A double-blind study of zomepirac sodium and placebo in the treatment of muscle contraction headache. Headache. 1981 Mar;21(2):45–48. doi: 10.1111/j.1526-4610.1981.hed2102045.x. [DOI] [PubMed] [Google Scholar]
  8. Kauppila A., Puolakka J., Ylikorkala O. The refief of primary dysmenorrhea by ketoprofen and indomethacin. Prostaglandins. 1979 Oct;18(4):647–653. doi: 10.1016/0090-6980(79)90032-7. [DOI] [PubMed] [Google Scholar]
  9. Kubota T., Komatsu H., Kawamoto H., Yamada T. Studies on the effects of anti-inflammatory action of benzoyl-hydrotropic acid (ketoprofen) and other drugs, with special reference to prostaglandin synthesis. Arch Int Pharmacodyn Ther. 1979 Jan;237(1):169–176. [PubMed] [Google Scholar]
  10. Lindegaard K. F., Ovrelid L., Sjaastad O. Naproxen in the prevention of migraine attacks. A double-blind placebo-controlled cross-over study. Headache. 1980 Mar;20(2):96–98. doi: 10.1111/j.1526-4610.1980.hed2002096.x. [DOI] [PubMed] [Google Scholar]
  11. Lundström V., Gréen K. Endogenous levels of prostaglandin F2alpha and its main metabolites in plasma and endometrium of normal and dysmenorrheic women. Am J Obstet Gynecol. 1978 Mar 15;130(6):640–646. doi: 10.1016/0002-9378(78)90320-4. [DOI] [PubMed] [Google Scholar]
  12. Lundström V. Treatment of primary dysmenorrhea with prostaglandin synthetase inhibitors--a promising therapeutic alternative. Acta Obstet Gynecol Scand. 1978;57(5):421–428. doi: 10.3109/00016347809156523. [DOI] [PubMed] [Google Scholar]
  13. Rosseel M. T., Bogaert M. G., Christiaens M., Verpooten G. A., De Broe M. E. Plasma levels of atenolol after haemodialysis in patients with end stage renal disease. Arch Int Pharmacodyn Ther. 1979 May;239(1):176–176. [PubMed] [Google Scholar]
  14. Sobczyk R. Dysmenorrhea: the neglected syndrome. J Reprod Med. 1980 Oct;25(4 Suppl):198–201. [PubMed] [Google Scholar]
  15. Stadel B. V. Oral contraceptives and cardiovascular disease (first of two parts). N Engl J Med. 1981 Sep 10;305(11):612–618. doi: 10.1056/NEJM198109103051104. [DOI] [PubMed] [Google Scholar]
  16. Vane J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232–235. doi: 10.1038/newbio231232a0. [DOI] [PubMed] [Google Scholar]
  17. Willman E. A., Collins W. P., Clayton S. G. Studies in the involvement of prostaglandins in uterine symptomatology and pathology. Br J Obstet Gynaecol. 1976 May;83(5):337–341. doi: 10.1111/j.1471-0528.1976.tb00839.x. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES